Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

New medical breakthrough by Bioheart for treatment of patients with heart disorders

Bioheart, Inc. offers yet another medical breakthrough with the next-level stem cell treatment for cardiac patients. The stem cells aid in limiting damage due to a cardiac event and promote angiogenesis or formation of new blood vessels.

1 Oct 2009

Houston Northwest Medical Center recognized as Cycle III Chest Pain Center with PCI

In its continuous pursuit of quality cardiac care, Houston Northwest Medical Center was proudly recognized as the first accredited chest pain center in Houston and one of a handful in Texas to be named a Cycle III Chest Pain Center with PCI (percutaneous coronary intervention).

30 Sep 2009

Orphan drug designation for pixantrone applied by Cell Therapeutics

Cell Therapeutics, Inc. ("CTI") announced today that it has applied to the European Medicines Agency (EMEA) for orphan drug designation for pixantrone. CTI initiated the process of obtaining marketing approval in Europe in July, 2009, for the treatment of relapsed or refractory aggressive NHL.

30 Sep 2009

St. Jude Medical launches new cardiac rhythm management devices

St. Jude Medical, Inc. today announced it has launched several new cardiac rhythm management devices for the treatment and diagnosis of abnormal heart rhythms.

30 Sep 2009

CIHR and CMAJ honour eight Canadian Health Researchers

The Canadian Institutes of Health Research (CIHR) and the Canadian Medical Association Journal (CMAJ) today honoured eight outstanding Canadian individuals and teams with the first ever CIHR-CMAJ Top Canadian Achievements in Health Research Awards, which recognize and celebrate Canadian health research and innovation excellence.

29 Sep 2009

Hospital-at-home care favorable to traditional hospital care

Hospital-at-home care may be a practical alternative to traditional hospital inpatient care for patients with acutely decompensated (suddenly worsening) chronic heart failure, according to a report in the September 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

29 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

Study links diabetes to atrial fibrillation in women

Diabetes increases by 26 percent the likelihood that women will develop atrial fibrillation (AF), a potentially dangerous irregular heart rhythm that can lead to stroke, heart failure, and chronic fatigue. These are the findings of a new Kaiser Permanente study, published in the October issue of Diabetes Care, a journal of the American Diabetes Association.

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

Research to develop small-molecule drug that blocks excess iron absorption

Excess iron in the body, if left unchecked, can form toxic deposits in major organs leading to serious conditions including heart failure, diabetes, liver cirrhosis, arthritis, and even infertility. Iron overload can be a consequence of a genetically mutated gene known as hereditary hemochromatosis, or a consequence of red blood cell transfusions, required as life saving treatments, for patients with diseases such as thalassemia.

25 Sep 2009

Matrix metalloproteinase-8 enzyme increases the risk of heart diseases

Scientists at Queen Mary, University of London have made an important discovery in understanding what causes arteries to clog up. They have discovered that an enzyme called matrix metalloproteinase-8 plays a crucial role in raising blood pressure and causing abnormal build-up of cells in the arteries - both of which increase the risk of heart disease.

25 Sep 2009

$Cardiogenesis sponsors educational symposium on refractory angina treatment method$

Cardiogenesis sponsors educational symposium on refractory angina treatment method

Cardiogenesis Corporation, a market leader in laser transmyocardial revascularization (TMR), today announced that it sponsored an educational symposium yesterday in conjunction with the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco.

24 Sep 2009

KORE Telematics certifies MedApps telehealth solutions for use on its network

American Telemedicine Association Mid-Year Meeting—KORE Telematics, the world’s largest digital wireless services provider specializing in machine-to-machine (M2M) communications, today announced that MedApps telehealth solutions are now certified for use on the KORE network.

24 Sep 2009

NIH awards $2.5 million grant to University of Utah cardiologist

A pioneering model that a University of Utah cardiologist proposes as a cause of heart disease is the kind of creative thinking the National Institutes of Health (NIH) likes to see-and reward with one of its most prestigious honors, a $2.5 million 2009 Pioneer Award.

24 Sep 2009

MACH II clinical trial results revealed

Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced new clinical data from Academic Medical Center’s (AMC) three-year follow-up results from patients in the Impella 2.5 arm of the MACH II trial, revealing improved left ventricular function, cardiac output and quality of life.

24 Sep 2009

SynCardia Systems and AorTech International sign technology license agreement

On Sept. 22, SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, announced an exclusive technology licensing agreement with AorTech International plc (AIM: AOR).

23 Sep 2009

Genous Bio-engineered R stent for STEMI implantation exhibits safety

OrbusNeich announced today that interim data from a prospective registry showed good safety in a broad population of patients that underwent primary percutaneous coronary intervention (PCI) and implantation of the company's Genous Bio-engineered R stent for ST-elevation myocardial infarction (STEMI).

23 Sep 2009

Women have higher incidence of stroke and mortality than men

Even though the incidence of atrial fibrillation is higher in men than women, a review of past studies and medical literature completed by cardiac experts at Rush University Medical Center shows that women are more likely than men to experience symptomatic attacks, a higher frequency of recurrences, and significantly higher heart rates during atrial fibrillation, which increases the risk of stroke.

23 Sep 2009

Abiomed announces new data from its USpella IRB registry of Impella 2.5 patients

Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced new clinical data from USpella, the first U.S. multicenter registry of Impella 2.5 patients evaluating the safety and feasibility of left ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention (PCI) and treatment of acute myocardial infarction (AMI).

23 Sep 2009

Hormone therapy for treating prostate cancer is linked to heart problems

Berlin, Germany: New research has found that hormone therapy used to treat men with advanced prostate cancer is associated with an increased chance of developing various heart problems. Some choices of therapy appear, however, to be less risky than others.

22 Sep 2009